contributes to cancer development and progression in various types of malignancy including cervical cancer. Human papillomavirus, a necessary cause of cervical cancer, induces COX-2 expression via E5, E6 and E7 oncoproteins, which leads to prostaglandin E2 increase and the loss of E-cadherin, promotes cell proliferation and production of vascular endothelial growth factor. It is strongly suggested that COX-2 is associated with cancer development and progression such as lymph node metastasis. Many studies have suggested that non-selective COX-2 inhibitors such as non-steroidal anti-inflammatory drugs (NSAIDs), and selective COX-2 inhibitors might show anti-cancer activity in COX-2 -dependent and -independent manners. Two phase II trials for patients with locally advanced cervical cancer showed that celecoxib increased toxicities associated with radiotherapy. Contrary to these discouraging results, two phase II clinical trials, using rofecoxib and celecoxib, demonstrated the promising chemopreventive effect for patients with cervical intraepithelial neoplasia 2 or 3. However, these agents cause a rare, but serious, cardiovascular complication in spite of gastrointestinal protection in comparison with NSAIDs. Recent pharmacogenomic studies have showed that the new strategy for overcoming the limitation in clinical application of COX-2 inhibitors shed light on the use of them as a chemopreventive method. (J Cancer Prev 2013;18:123-134) 
INTRODUCTION
Cyclooxygenase (COX) pathway is known to be one of major routes for producing bioactive prostanoids such as prostaglandin (PG) E2, D2, F2α, I2 (prostacyclin) and thromboxane (TX) A2. COX exists as at least two different enzymes in mammalian cells: COX-1 and COX-2, which are located on human chromosomes 9 and 1 respectively. 1, 2 COX-1 is constitutively expressed in many normal cells, and PGs produced by COX-1 are important for maintaining the integrity of gastric mucosa and allowing normal platelet aggregation and renal function. On the other hand, COX-2 is induced by oncogene, growth factors and cytokines, and COX-2-derived PGs can stimulate cell proliferation, promote angiogenesis, increase invasiveness and adhesion to the extracellular matrix and inhibit immune surveillance and apoptosis. [3] [4] [5] Furthermore, COX-2-derived PGs have been shown to contribute to cancer development, progression and metastasis. 6 Therefore, the inhibition of COX-2 has been anticipated to prevent the development and progression of cancer and to promote the response to cytotoxic agents as well as ionizing radiation. 7 Although non-steroidal anti-inflammatory drugs (NSAIDs), which non-specifically inhibit both COX-1 and COX-2, induce adverse effects on gastrointestinal (GI) tract, selective COX-2 inhibitors such as rofecoxib and celecoxib reduce the adverse effects of NSAIDs on GI tract with relief of chronic pain. 8, 9 However, selective COX-2 inhibitors are known to be associated with increased cardiovascular adverse effects. 10 Since many preclinical and clinical studies have shown that COX-2-derived PGs are associated with cervical neoplasia and COX-2 inhibitors have anti-cancer effect, we will show the role of COX-2 and the efficacy of COX-2 inhibitors in cervical neoplasia, and will suggest the new strategy for overcoming the limitation in clinical application of COX-2 inhibitors through this review.
COX-2, INFLAMMATION AND CARCINOGENESIS
Chronic inflammation mediated by COX-2 is associated with carcinogenesis and cancer progression. It is caused by various factors including bacterial infections and chemical irritants. The longer the inflammation persists, the higher is the risk of associated carcinogenesis. Moreover, neoplasia could be caused by inflammatory mediators inducing preneoplastic mutation, stimulation of angiogenesis and resistance to apoptosis, and these inflammatory mediators may activate signaling molecules involved in inflammation and carcinogenesis such as COX-2 and nuclear factorkappa B (NF-kB).
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Carcinogenesis by COX-2 has been explored in terms of the inhibition of apoptosis, promotion of angiogenesis, invasiveness and immunosuppression in various types of malignancy. 7 Especially, PG E2, an end product of COX-2, may increase the activity of mitogen-activated protein kinase (MAPK), 12 affect ras-controlled signal transduction pathways, 13 and suppress the activity of caspase-3, a key enzyme in apoptotic process. 14 Besides, COX-2-derived PGs may increase the production of vascular endothelial growth factor (VEGF) and promote neovascularization in cancer. oncoprotein also induces the transcription of COX-2 gene in a ligand-dependent and -independent activation of epidermal growth factor receptor (EGFR) and MAPK cascade, [20] [21] [22] and causes the increased expression of VEGF by activating MEK/ERK 1/2 and PI3K/Akt, which are associated with cervical carcinogenesis (Fig. 1B) . 20, 23, 24 Moreover, chronic infection of HPV in cervical epithelium increases PG E2 by COX-2, which leads to the loss of E-cadherin, increased cell proliferation and production of VEGF.
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COX-2 EXPRESSION IN CERVICAL CARCINOGENESIS
COX-2 is highly expressed in various types of cervical neoplasm such as cervical intraepithelial neoplasia (CIN) (7.4%), adenocarcinoma (13%) and squamous cell carcinoma (28.8%) of cervix, suggesting that COX-2 expression can be associated clinically with cervical cancer development and progression. [28] [29] [30] Besides, COX-2 gene has been shown to be involved in early cervical carcinogenesis and accelerate tumor progression by increasing VEGF. 25 COX-2 has been also shown to be expressed in dysplastic This fact is contrary to previous studies of COX-2 overexpression in colon cancer where the increased COX-2 expression in stromal cells was related with carcinogenesis, suggesting that PGs derived from COX-2 in stromal cells would be secreted and bind to receptors on adjacent epithelial cells, then might promote carcinogenesis with the "landscaping effect". 32 Unlike colon cancer, the landscaping effect of stromal cells seems to have no role in cervical carcinogenesis because it may be influenced by HPV itself.
Interestingly, COX-2 overexpression may be also associated with old age and menopause in CIN. 31 Although the reason is unclear, the lack of progesterone for menopausal women could explain this fact because progesterone has been shown to suppress COX-2 expression in some cells. On the other hand, COX expression in cervical cancer may be associated with the effect of radiotherapy. 55, 56 Especially, COX-1 expression decreases significantly radiosensitivity in cervical cancer cell lines in spite of no association between COX-2 expression and radio-resistance. These data suggest that COX-1 might imply more importance than COX-2 regarding the innate radiosensitivity of cervical cancer, and that NSAIDs, non-selective Furthermore, the Radiation Therapy Oncology Group (RTOG) 0128 trial was performed as a phase II study to evaluate the efficacy and toxicity of celecoxib and chemoradiation for patients with locally advanced cervical cancer. In this study, 83 patients were treated with chemoradiation using cisplatin and 5-fluorouracil with the addition of celecoxib at the dose of 400 mg twice daily for 1 year. However, grade 3 or 4 toxicities were developed in 47% and late toxicities such as GI and genitourinary side effects were observed in 13% of all patients, which were higher than expected rates of complication. These data suggest that the toxicities associated with celecoxib may limit the use of this drug. 60 On the other hand, a randomized clinical trial showed that the treatment of oxyphenbutazone, a non-selective COX-2 inhibitor, at the dose of 300 mg daily improved 5-and 10-year survival rates, compared to placebo in patients undergoing radiotherapy only for cervical cancer 
ADVERSE EFFECTS OF COX-2 INHIBITORS
After selective COX-2 inhibitors were introduced as alternative analgesics to NSAIDs due to fewer GI side effects, the approval of rofecoxib (Vioxx Ⓡ ) and celecoxib Moreover, selective COX-2 inhibitors had been investi- group. 66 Furthermore, rofecoxib has been shown to increase cardiovascular adverse effects by meta-analysis when compared to placebo or NSAIDs (Table 2 ).
Benefit and risk by COX-2 inhibitors are summarized in Fig. 2 . In spite of markedly less GI damage than NSAIDs, selective COX-2 inhibitors are doomed to increase cardiovascular adverse effects because selective COX-2 inhibition may reduce the production of prostacyclin, which normally inhibits platelet aggregation and vasodilation, while still allowing COX-1 mediated synthesis of TX A2 to induce platelet aggregation and vasoconstriction. 67 After withdrawal of rofecoxib, the safety of celecoxib has also been investigated for cardiovascular adverse effects. Celecoxib has been shown to be safer than rofecoxib in most studies. The first reason is that the degree of COX-2 selectivity of celecoxib is a fifth of that of rofecoxib. Actually, the degree of COX-2 selectivity is known to correlate with cardiovascular and renal risks.
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The second reason is that a reactive metabolite of rofecoxib, a maleic anhydride derivative which contributes to atherothrombosis, cannot be derived from other COX-2 inhibitors including celecoxib, valdecoxib and lumaricoxib. 70 Furthermore, the Celecoxib Long-term Arthritis Safety Study (CLASS) demonstrated no significant difference in Fig. 2 . Role of cyclooxygenase (COX) in human gastrointestinal, cardiovascular and renal functions. COX-1-derived thromboxane A2 decreases gastric acid secretion in gastrointestinal tract and renal vascular resistance in kidney, whereas it increases mucus production in gastrointestinal tract, vasoconstriction, platelet aggregation and smooth muscle proliferation in blood vessel, and vasodilation in kidney. Moreover, COX-2-derived prostaglandins E2 and I2 decrease platelet aggregation and smooth muscle proliferation in blood vessel while they increase vasodilation in gastrointestinal tract and blood vessel, and diuresis and natriuresis in kidney. On the other hand, selective COX-2 inhibitors increase thromboembolic risk, and decrease gastrointestinal side effects and renal function.
cardiovascular event between celecoxib 800 mg/day and NSAIDs, suggesting the safety of celecoxib. properties. Much of its beneficial effect is found to be due to its inhibition of NF-kB and subsequent inhibition of proinflammatory pathways. 74 Besides, curcumin synergistically augments the growth inhibitory effect of celecoxib by down-regulating COX-2 mRNA expression and inhibition of the catalytic activity of 5-lipoxygenase producing leukotrienes associated with carcinogenic process. 75 Phase I trials on curcumin showed that it is safe to human up to 12,000 mg/day when taken orally and caused histological improvement of precancerous lesions including CIN. [76] [77] [78] Moreover, curcumin has been shown to confer the radiosensitizing effect in cervical cancer cells. . 84 However, it should be considered that PPIs may be associated with adverse effects independent of concomitant NSAID use, including pneumonia, bacterial diarrhea and hip fracture. [85] [86] [87] Moreover, it can be considered that selective COX-2 inhibitors are combined with low-dose aspirin for cardioprotection. However, the CLASS trial demonstrated that a fourfold increase in the incidence of GI bleeding occurred in a subgroup of patients taking celecoxib in combination with aspirin, suggesting that the combination should not be used in patients with high-risk GI bleeding. 71 Furthermore, curcumin can be combined with selective COX-2 inhibitors because it induces cardioprotective effect by scavenging oxygen-free radical. 88 However, large and well-controlled clinical trials are required to determine the role of selective COX-2 inhibitors and curcumin to prevent and treat cancer. 
